Nephrology emergency · KIMS Secunderabad
Goodpasture Syndrome (Anti-GBM Disease) — A Nephrology Emergency Requiring Immediate Treatment
Goodpasture syndrome is an autoimmune condition in which the immune system produces antibodies against the glomerular basement membrane (GBM) — the structural filter at the core of the kidney's glomerulus. These anti-GBM antibodies attack not only the kidneys but also the alveolar basement membrane in the lungs, causing simultaneous rapidly progressive glomerulonephritis (RPGN) and pulmonary haemorrhage. It is one of the most dramatic and most dangerous nephrology emergencies: a patient may go from normal kidney function to dialysis dependence within days to weeks, while simultaneously coughing up blood from lung haemorrhage.
Early diagnosis and immediate treatment — plasma exchange to remove the anti-GBM antibodies, combined with high-dose steroids and cyclophosphamide to suppress further antibody production — can preserve kidney function and prevent respiratory failure. Delayed treatment, even by days, allows irreversible crescentic glomerulonephritis to destroy kidney tissue that cannot be recovered. This page explains the disease, how it is diagnosed at KIMS, and why the speed of diagnosis — which depends on immediately available anti-GBM antibody testing and kidney biopsy with electron microscopy — is the most critical variable in the outcome.
The mechanism — why the body attacks its own kidneys
The target of anti-GBM antibodies is the alpha-3 chain of type IV collagen — a specific protein within the glomerular basement membrane. In healthy individuals, this protein is sequestered within the GBM and not exposed to the immune system. In susceptible individuals — those with a specific HLA-DR15 genetic background, often triggered by an environmental event such as hydrocarbon exposure, smoking, or a respiratory infection — the immune system becomes sensitised to this protein and produces anti-GBM IgG antibodies.
These antibodies bind to the alpha-3 chain of type IV collagen in the GBM, activating complement and triggering a devastating inflammatory response — neutrophil recruitment, rupture of the glomerular capillary wall, cellular crescent formation, and fibrin deposition. Within days, a substantial proportion of glomeruli may be affected by crescents. The same alpha-3 chain of type IV collagen is present in the alveolar basement membrane of the lungs, which is why pulmonary haemorrhage accompanies kidney disease in 60 to 70% of cases.
Symptoms and clinical presentation
Clinical features requiring same-day evaluation
Any one of the following — and especially several together — warrants urgent anti-GBM antibody testing, urine microscopy, and kidney function testing:
Pulmonary haemorrhage — haemoptysis (coughing blood), breathlessness, and chest tightness. Pulmonary haemorrhage can be massive and life-threatening. Chest X-ray shows bilateral alveolar infiltrates.
Rapidly progressive kidney failure — creatinine rises dramatically over days to weeks. Haematuria (often macroscopic — visible blood in urine) and heavy proteinuria. Oliguria as kidney function deteriorates.
Anaemia — from pulmonary haemorrhage (iron deficiency from chronic blood loss) and from kidney failure.
Non-specific constitutional features — fatigue, pallor. Hypertension develops as kidney function declines.
Pure renal presentation — approximately 30 to 40% of anti-GBM disease presents with kidney involvement only, without clinical lung haemorrhage. These patients are detected by blood tests showing rapidly rising creatinine, and haematuria on urine testing.
Goodpasture syndrome is a medical emergency. The combination of haemoptysis (coughing blood), rapidly worsening kidney function, and haematuria requires same-day emergency evaluation. Do not wait for an outpatient appointment. Call KIMS on 040-4488-5000 or proceed to the emergency department immediately.
Diagnosis — speed is the critical variable
Anti-GBM antibody (serum)
The diagnostic test — a high-specificity assay for circulating anti-GBM IgG. A strongly positive result in the context of RPGN and/or pulmonary haemorrhage is effectively diagnostic. Results within 24 to 48 hours allow urgent treatment to begin before the biopsy result is available in life-threatening presentations. Anti-ANCA antibodies are simultaneously measured — 20 to 30% of anti-GBM disease cases are also ANCA-positive (double-positive), which carries a different prognosis and may require additional immunosuppression.
Kidney biopsy with NABL LM + IF + EM at KIMS
The kidney biopsy is the gold standard diagnostic test and the most important prognostic investigation. Light microscopy (LM) shows necrotising crescentic glomerulonephritis — often with more than 50% of glomeruli showing crescents, reflecting the severity of the attack. Immunofluorescence (IF) shows the diagnostic finding: linear IgG staining along the glomerular basement membrane — the characteristic 'tram-track' linear pattern that distinguishes anti-GBM disease from the granular immune complex deposits of other GN subtypes. Electron microscopy (EM) — performed in-house at KIMS's NABL laboratory — confirms the absence of electron-dense immune complex deposits, supporting the anti-GBM diagnosis and excluding concurrent immune complex GN. EM is particularly important in double-positive cases.
Bronchoalveolar lavage (BAL)
In patients with haemoptysis or bilateral pulmonary infiltrates, BAL confirms alveolar haemorrhage — haemosiderin-laden macrophages in the lavage fluid are a specific marker of prior or ongoing alveolar bleeding. BAL also excludes infection as an alternative cause of pulmonary infiltrates.
Treatment — the urgency cannot be overstated
Plasma exchange — the critical first treatment
Plasma exchange (plasmapheresis) removes circulating anti-GBM antibodies from the blood. Large volumes of plasma (typically 4 litres per session) are removed and replaced with fresh frozen plasma or albumin. Daily plasma exchange for 14 days removes the majority of circulating anti-GBM antibodies, reducing the ongoing attack on the kidneys and lungs. For active pulmonary haemorrhage — where alveolar bleeding can be immediately life-threatening — plasma exchange with FFP replacement (rather than albumin) is preferred to avoid further depletion of clotting factors. Plasma exchange is available at KIMS for Goodpasture syndrome management.
Immunosuppression — preventing new antibody production
While plasma exchange removes existing anti-GBM antibodies, new antibody production continues unless suppressed. The standard immunosuppression regimen: high-dose prednisolone (1mg/kg/day, maximum 60–80mg, tapering) plus oral cyclophosphamide (2–3mg/kg/day) for 3 months. This combination suppresses B-cell and T-cell activity, reducing new anti-GBM antibody synthesis. Anti-GBM antibody levels are monitored weekly during treatment — the goal is to drive the titre to zero. Once the anti-GBM antibody has become undetectable and treatment is completed, relapse is uncommon — distinguishing anti-GBM disease from ANCA vasculitis, where relapse is much more frequent.
Prognosis — the importance of timing
Outcomes in anti-GBM disease depend almost entirely on the kidney function at presentation and the proportion of crescentic glomeruli on biopsy. The window for kidney recovery is measured in days, not weeks — the cards below summarise the prognostic bands used at KIMS.
Creatinine below 500 µmol/L (kidney function partially preserved)
Good — majority avoid permanent dialysis. Kidney function often recoverable with prompt plasma exchange and immunosuppression.
Creatinine 500–600 µmol/L (severe kidney injury)
Moderate — approximately 50% avoid permanent dialysis. Biopsy crescent percentage is the key prognostic variable.
Creatinine above 600 µmol/L or dialysis-dependent at presentation
Poor for kidney recovery — less than 10% come off dialysis permanently. Immunosuppression still given for lung protection. Transplant considered after anti-GBM antibody clearance (at least 6–12 months).
Oliguria or anuria for more than 72 hours at presentation
Very poor for kidney recovery regardless of treatment.
Pulmonary haemorrhage with preserved kidney function
Good outcome overall — aggressive plasma exchange protects lungs and residual kidney function.
The biopsy finding of crescents in more than 50% of glomeruli is the most powerful predictor of dialysis dependence. However, even patients with extensive crescentic disease deserve a trial of treatment — some recover surprisingly well, and immunosuppression is also required to protect the lungs regardless of kidney outcome.
Kidney transplant after Goodpasture syndrome
Patients who reach end-stage renal disease from Goodpasture syndrome are candidates for kidney transplantation — but only after the anti-GBM antibody has been undetectable for at least 6 to 12 months.
Transplanting into a patient with circulating anti-GBM antibodies risks immediate recurrence of anti-GBM disease in the transplanted kidney. At KIMS, anti-GBM antibody levels are monitored at 3-monthly intervals after treatment — transplant evaluation begins when the antibody is undetectable and has remained so for 6 months.
Book an Emergency Nephrology Consultation at KIMS
Frequently Asked Questions — Goodpasture Syndrome
Anti-GBM disease is the broader term — it refers to the autoimmune condition caused by anti-glomerular basement membrane antibodies. Goodpasture syndrome specifically refers to the clinical presentation where both lung haemorrhage and kidney disease are present simultaneously — the pulmonary-renal syndrome caused by anti-GBM antibodies. Not all patients with anti-GBM disease have lung involvement (approximately 30 to 40% have kidney-only disease); these patients have anti-GBM disease but strictly speaking do not have Goodpasture syndrome. In clinical practice, the two terms are often used interchangeably.
Anti-GBM disease can reduce kidney function from normal to dialysis-dependence within 1 to 4 weeks. The crescentic glomerulonephritis progresses rapidly once triggered — each day without treatment allows more glomeruli to develop crescents. This is why anti-GBM disease is treated as a medical emergency: diagnostic testing, kidney biopsy, and plasma exchange initiation should all occur within 24 to 72 hours of presentation. Patients who are treated within this window have significantly better kidney outcomes than those whose treatment is delayed.
Anti-GBM disease results from an immune response against the alpha-3 chain of type IV collagen — a normal structural protein of the glomerular basement membrane. The trigger for this immune response is not fully understood, but environmental factors that damage the alveolar epithelium — cigarette smoking (the most important risk factor for pulmonary haemorrhage in anti-GBM disease), hydrocarbon solvent exposure, cocaine inhalation, and preceding respiratory infections — are associated with triggering the condition in genetically susceptible individuals (HLA-DR15 positive). The condition is not hereditary and does not typically recur after complete treatment.
Cigarette smoking does not cause anti-GBM disease — the antibodies are triggered by a specific immune response that requires genetic susceptibility. However, smoking dramatically increases the risk of pulmonary haemorrhage in patients who already have anti-GBM antibodies. The explanation: the alveolar basement membrane is normally not accessible to circulating anti-GBM antibodies in non-smokers because the blood-air barrier is intact. Smoking damages the alveolar epithelium, exposing the underlying basement membrane to circulating anti-GBM antibodies — triggering haemorrhage. This is why Goodpasture syndrome with lung involvement is much more common in smokers than non-smokers, even when the anti-GBM antibody titre is similar.
Linear IgG staining is the pathognomonic immunofluorescence finding in anti-GBM disease. When the kidney biopsy tissue is stained with fluorescent antibodies against IgG, the anti-GBM antibodies that have deposited along the entire length of the glomerular basement membrane appear as a continuous, smooth, brightly fluorescent linear pattern — like paint applied uniformly along the GBM. This is distinct from the granular (lumpy-bumpy) IgG staining of immune complex glomerulonephritis (IgA nephropathy, lupus, MPGN), where immune complexes deposit in discrete foci rather than uniformly. The linear IgG pattern on immunofluorescence is diagnostic of anti-GBM disease and is performed in-house at KIMS's NABL-accredited laboratory.
Recovery depends primarily on the creatinine at presentation and the proportion of glomeruli showing crescents on biopsy. Patients presenting with creatinine below 500 µmol/L have a good chance of avoiding permanent dialysis with prompt plasma exchange and immunosuppression. Patients who are dialysis-dependent at presentation have a less than 10% chance of recovering sufficient kidney function to come off dialysis — because by this stage, the majority of glomeruli have been destroyed by crescents. The lesson is brutal and important: the window for kidney recovery in anti-GBM disease is measured in days, not weeks.
Anti-GBM disease is one of the few autoimmune kidney conditions that does not typically relapse after successful treatment. Once the anti-GBM antibody titre is driven to zero with plasma exchange and immunosuppression, and treatment is completed, the anti-GBM antibody usually remains absent indefinitely. This is in contrast to ANCA vasculitis, which has a 30 to 50% relapse rate. However, the anti-GBM antibody is monitored 3-monthly for at least 12 months after treatment to confirm clearance. Kidney transplant cannot be performed until the antibody has been undetectable for at least 6 months.
KIMS Secunderabad — Dr. Aswini Dutt T (glomerular disease subspecialty), immediate anti-GBM antibody testing, kidney biopsy with NABL LM + IF + EM in-house (linear IgG staining and EM performed in-house — not outsourced), plasma exchange capability, CRRT 24/7 for dialysis support during acute phase, long-term anti-GBM antibody monitoring, transplant evaluation after antibody clearance. Emergency nephrology available 24/7 — call 040-4488-5000.